Acne | Xenon | XPF-005-101
Pharmaceutical Company/Sponsor:
Xenon
Code:
XPF-005-101
Title:
A phase 1 and 2 randomized, double-blind, vehicle-controlled, parallel-group study to evaluate the safety, tolerability, efficacy, and exposure of up to 12 weeks of XPF-005 treatment in healthy volunteers and subjects with acne vulgaris
Type:
Phase:
Condition/Disease:
Acne
Intervention(s)/Treatment(s):
Status:
Completed
Link for Additional Information:
